The Canadian authorisation moves Light AI’s AI-enabled throat-image analysis platform from investigational development into its first regulated market, providing healthcare professionals with a software-based tool to support assessment of suspected Group A Streptococcus infection.

The amended agreement strengthens Exor's long-term commitment to Philips while allowing the healthcare technology investor to increase its maximum shareholding from 20% to 22%.

Acquisition adds FDA-authorised fibromyalgia therapy and strengthens smartphone-based digital health offering

The Claria System is designed to improve safety and efficiency during minimally invasive hysterectomy procedures by providing a controlled tissue extraction approach.

The latest agreement strengthens the companies’ collaboration as they target a major central nervous system indication using AI-powered drug discovery.

iPredict-DR uses artificial intelligence to analyse retinal images and support earlier detection of diabetic eye disease.

Zeta Surgical’s robotic navigation platform uses AI and computer vision to improve precision and repeatability during transcranial magnetic stimulation procedures.

The ALARION-EV trial will evaluate AtaCor Medical’s investigational parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to provide an alternative approach to traditional ICD therapy for patients at risk of life-threatening arrhythmias.

The new funding will accelerate manufacturing and commercial deployment of the FDA-cleared Marie system, which reimagines proton therapy by rotating the patient instead of the treatment machine.

The DE STSF platform combines radiofrequency and pulsed field ablation in a single catheter, expanding treatment options for electrophysiologists managing complex cardiac arrhythmias.

The AI-powered software analyses retinal images captured by the widely used iCare DRSplus camera, supporting earlier detection of diabetic retinopathy in primary care and community healthcare settings.

The US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA) have announced a new formal collaboration initiative

Swiss medical device company Distalmotion has secured additional US Food and Drug Administration (FDA) 510(k) clearance for its DEXTER robotic surgery system, further expanding its role in minimally invasive gynaecological procedures.

KARL STORZ has received US Food and Drug Administration (FDA) clearance for its RUBINA Lens exoscope, enabling the company to bring its near-infrared (NIR) fluorescence imaging technology into open surgical procedures.

Subtle Medical has received FDA clearance for SubtleHD(CT), an AI-powered software platform designed to improve computed tomography (CT) image quality by reducing noise and enhancing low-contrast detectability.

The company expands into vaccine-led prevention as pharma shifts focus toward long-term disease risk reduction driven by infection-linked chronic outcomes and antimicrobial resistance.

The acquisition combines diagnostic imaging scale with growing AI capabilities as healthcare investors target data-rich clinical infrastructure.

The combination forms one of the largest dedicated healthcare investors globally, spanning pharma, medtech, diagnostics, and healthcare infrastructure across three continents.

The deal gives Regeneron access to Helicon peptide technology as pharma companies race to unlock previously “undruggable” intracellular targets.

Strengthening its structural heart pipeline, Boston Scientific expands into next-generation transcatheter aortic valve technology with an optional full acquisition pathway.